Regeneron Pharmaceuticals (NASDAQ:REGN) Cut to Hold at Wall Street Zen

Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report issued on Saturday.

A number of other brokerages have also recently issued reports on REGN. BMO Capital Markets reduced their target price on shares of Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating for the company in a research report on Monday, May 18th. Leerink Partners reaffirmed a “market perform” rating and set a $641.00 price target (down from $792.00) on shares of Regeneron Pharmaceuticals in a research report on Monday, May 18th. Canaccord Genuity Group dropped their price objective on shares of Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating for the company in a research note on Tuesday, May 19th. TD Cowen boosted their price objective on shares of Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the company a “buy” rating in a report on Thursday, April 23rd. Finally, Truist Financial decreased their target price on shares of Regeneron Pharmaceuticals from $796.00 to $778.00 and set a “buy” rating on the stock in a research report on Monday, May 18th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $792.65.

Regeneron Pharmaceuticals Stock Performance

REGN opened at $654.27 on Friday. The business has a fifty day simple moving average of $652.48 and a 200 day simple moving average of $725.50. The company has a market capitalization of $69.17 billion, a PE ratio of 15.94, a price-to-earnings-growth ratio of 1.44 and a beta of 0.24. Regeneron Pharmaceuticals has a 1 year low of $532.60 and a 1 year high of $821.11. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.57 and a quick ratio of 2.96.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, beating analysts’ consensus estimates of $8.91 by $0.56. The firm had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The company’s revenue for the quarter was up 19.0% on a year-over-year basis. During the same period in the prior year, the firm posted $8.22 EPS. Research analysts expect that Regeneron Pharmaceuticals will post 37.44 EPS for the current year.

Insider Activity at Regeneron Pharmaceuticals

In related news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $705.24, for a total value of $70,524.00. Following the transaction, the director owned 17,503 shares in the company, valued at approximately $12,343,815.72. This trade represents a 0.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.97% of the company’s stock.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Large investors have recently bought and sold shares of the company. WPG Advisers LLC increased its holdings in Regeneron Pharmaceuticals by 312.5% in the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 25 shares during the period. Western Wealth Management LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 1st quarter valued at approximately $26,000. SHP Wealth Management bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $26,000. Titan Wealth CI Ltd bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $29,000. Finally, Board of the Pension Protection Fund acquired a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $31,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.